Silence Therapeutics this week announced that it has struck a deal under which its delivery technologies will be evaluated by Australian microRNA drug developer Mireven for use with its therapeutic candidates.

Silence will formulate a mimic of miR-7 using its three lipid-based delivery technologies: AtuPlex, which is used in the company's phase I siRNA cancer drug Atu-027; DACC, which selectively targets the lung endothelium; and DBTC, which targets liver cells.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

New Mexico is re-doing its proposed science education standards after criticism, the Associated Press reports.

Agbio executives say gene editing will speed up breeding efforts, according to the Wall Street Journal.

La Trobe University's Jenny Graves has won the $250,000 Prime Minister's Prize for Science, the Guardian reports.

In Cell this week: post-treatment changes to melanoma genome, multi-omics analysis of muscle-invasive bladder cancer, and more.